How it works
ZAVESCA® (miglustat) reduces the harmful buildup of glycosphingolipids
In people with type 1 Gaucher disease, the body has an excess of fatty substances called glycosphingolipids (gli-coh-sfing-goh-lip-ids), or GSLs. That's because the body does not have enough of a certain enzyme that helps break down the GSLs.
GSLs may then build up over time. ZAVESCA helps reduce the amount of GSLs the body makes.* This way, the enzymes you do have are able to break them down.
*Based on laboratory studies.
About ZAVESCA
People with type 1 Gaucher disease also may have lowered levels of hemoglobin (a substance in red blood cells) and platelets (blood-clotting cells) that may cause anemia (low red blood cell count).1
ZAVESCA reduces the harmful buildup of glycosphingolipids throughout the body to help treat some of the symptoms of mild to moderate type 1 Gaucher disease in adult patients.2
Clinical studies have shown that ZAVESCA provides important benefits for people with mild to moderate type 1 Gaucher disease, whether they have been treated before with enzyme replacement therapy (ERT) or they are being treated for the first time.2 Individual results may vary.
ZAVESCA2:
- Reduced swelling of the liver
- Reduced swelling of the spleen